Search results
Results from the WOW.Com Content Network
Levosalbutamol is the INN while levalbuterol is the USAN. Levalbuterol was approved in the United States as a solution to be used with a nebulizer device in March 1999 [7] and in March 2015 became available in a formulation with a metered-dose inhaler under the trade name Xopenex HFA (levalbuterol tartrate inhalation aerosol). [8]
Salbutamol, also known as albuterol and sold under the brand name Ventolin among others, [1] is a medication that opens up the medium and large airways in the lungs. [8] It is a short-acting β 2 adrenergic receptor agonist that causes relaxation of airway smooth muscle. [8]
Ipratropium bromide/salbutamol, sold under the brand name Combivent among others, is a combination medication used to treat chronic obstructive pulmonary disease (COPD). [1] [4] [5] It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β 2-adrenergic agonist).
In April 2005, FDA advisors requested that Pfizer place a boxed warning on their non-steroidal anti-inflammatory drug Celebrex for cardiovascular and gastrointestinal risks. [9] [10] In 2005, the FDA issued a boxed warning regarding the risk of atypical antipsychotics being prescribed among elderly patients with dementia. This advisory was ...
The Beers Criteria for Potentially Inappropriate Medication Use in Older Adults, commonly called the Beers List, [1] are guidelines published by the American Geriatrics Society (AGS) for healthcare professionals to help improve the safety of prescribing medications for adults 65 years and older in all except palliative settings.
The Torch study demonstrated benefits in terms of quality of life and lung function of salmeterol alone or in combination with inhaled corticosteroids in patients with COPD [11] In exercise-induced bronchospasm monotherapy may be indicated in patients without persistent asthma. LABAs should not be used to treat acute symptoms.
A risk management plan is a documented plan that describes the risks (adverse drug reactions and potential adverse reactions) associated with the use of a drug and how they are being handled (warning on drug label or on packet inserts of possible side effects which if observed should cause the patient to inform/see his physician and/or ...
LABAs are designed to reduce the need for shorter-acting β 2 agonists such as salbutamol (albuterol), as they have an approximately twelve-hour duration of action, compared to about five hours for salbutamol, making them candidates for sparing high doses of corticosteroids [citation needed] or treating nocturnal asthma and providing ...